Patents by Inventor Mingxin Qian
Mingxin Qian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230323484Abstract: A method for preparing test solution for pathogen detection purpose, system, kit, detection primer and method are provided. The method of preparing a test solution includes lysing the sample to be tested with a lysis buffer to release the nucleic acids contained in the sample to obtain a lysis buffer containing nucleic acids and/or pathogen nucleic acids; extracting the lysis buffer containing nucleic acids through a nucleic acid extraction device to obtain an extract containing host nucleic acids and/or pathogen nucleic acids; preparing the test solution for pathogen detection purposes from the extract. A large volume of samples can be used in the present application and it greatly improves sensitivity and specificity of the assay.Type: ApplicationFiled: August 27, 2021Publication date: October 12, 2023Inventors: M QIAN, Tongxin LI, Mingxin QIAN
-
Publication number: 20230107679Abstract: Disclosed in the present disclosure is a method for preparing (S)-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid and derivatives thereof, comprising: taking a racemate of a compound represented by Formula (I) or a racemate of a salt of the compound represented by Formula (I) as a substrate, and making a R-isomer of the compound represented by Formula (I) in the substrate react under the catalysis of oxidative dehydrogenase to generate imino acid represented by formula (II); and converting the imino acid represented by Formula (II) into an S-isomer of the compound represented by Formula (I) in the presence of pipecolic acid reductase and a coenzyme capable of supplying hydrogen anions. The present disclosure is featured by mild reaction condition, strong stereoselectivity, high reaction efficiency, high conversion rate, etc.Type: ApplicationFiled: April 23, 2019Publication date: April 6, 2023Applicants: Tongli Biomedical Co., Ltd., Zhejiang UniversityInventors: Jianping WU, Shuyun JU, Junwei SHI, Lirong YANG, Mingxin Qian
-
Publication number: 20220227766Abstract: Preparation method for a compound as shown in formula (I) and levo-praziquantel. A racemate of ester of the compound of formula (I) is used as a substrate, and reaction is performed under the catalysis of immobilized lipase to produce the compound of formula (I); a circulating fluidized bed reactor is used, the circulating fluidized bed reactor includes an external circulation system and a reaction column, the immobilized lipase is arranged in the reaction column, the substrate solution is circulated many times between the external circulation system and the reaction column, the reaction is performed in the reaction column. The preparation of levo-praziquantel includes the described preparation steps of the formula (I). The preparation method of formula (I) can significantly improve the utilization rate of enzyme and reduce the use ratio of enzyme/substrate, and has mild reaction conditions, strong stereoselectivity, high reaction efficiency.Type: ApplicationFiled: March 15, 2022Publication date: July 21, 2022Inventors: Jianping WU, Lingjiao TANG, Xiao ZHAN, Lirong YANG, Mingxin QIAN
-
Patent number: 10238756Abstract: The present invention relates to lipid-associated indocyanine green particles for enhanced functional high-resolution near-infrared fluorescence medical imaging of lymphatic vessels, lymph nodes, lymphatic abnormalities, tumors, and inflammation.Type: GrantFiled: May 29, 2015Date of Patent: March 26, 2019Assignee: Tongli Biomedical Co., Ltd.Inventors: Rodney J. Y. Ho, John C. Kraft, II, Mingxin Qian
-
Patent number: 9802934Abstract: The present disclosure relates to a process and new intermediates for the synthesis of (R)-praziquantel, which is obtained through four steps in proper order, that is, condensation reaction, reduction reaction, acylation reaction and ring-closing reaction, using (1R)-2-substituted-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid as starting material. Overall, the present disclosure provides a (R)-praziquantel product with higher optical purity through a process route that is more cost effective and environmentally friendly.Type: GrantFiled: January 11, 2017Date of Patent: October 31, 2017Assignee: TONGLI BIOMEDICAL CO., LTD.Inventor: Mingxin Qian
-
Patent number: 9657017Abstract: The present invention relates to a crystal form of (R)-praziquantel and a preparation method and uses thereof. The X-ray diffraction pattern (CuK? radiation) of the crystal form of (R)-praziquantel at 25° C. shows the following diffraction peaks: 2-Theta =6.9±0.2°, 8.3±0.2°, 15.1±0.2°, 17.4±0.2°, 19.8±0.2°, 21.9±0.2°, 24.3 ±0.2° or d=12.74±0.20 ?, 10.61±0.20 ?, 5.87±0.20 ?, 5.09±0.20 ?, 4.48±0.20 ?, 4.06±0.20 ?, 3.66±0.20 ?. Compared to the existing crystal form of praziquantel, the crystal form of the present invention has better solubility, better drug efficacy and better pharmacokinetic characteristics. The preparation method of the present invention has the following advantages: good reproducibility, environmentally friendly, low cost, and able to operate at a normal pressure and temperature, and suitable for large-scale production.Type: GrantFiled: October 16, 2014Date of Patent: May 23, 2017Assignee: Tongli Biomedical Co., Ltd.Inventors: Mingxin Qian, Rodney JY Ho, Chunsheng Qiao, Junwei Shi
-
Publication number: 20170121330Abstract: The present disclosure relates to a process and new intermediates for the synthesis of (R)-praziquantel, which is obtained through four steps in proper order, that is, condensation reaction, reduction reaction, acylation reaction and ring-closing reaction, using (1R)-2-substituted-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acid as starting material. Overall, the present disclosure provides a (R)-praziquantel product with higher optical purity through a process route that is more cost effective and environmentally friendly.Type: ApplicationFiled: January 11, 2017Publication date: May 4, 2017Inventor: Mingxin Qian
-
Publication number: 20160272636Abstract: The present invention relates to a crystal form of (R)-praziquantel and a preparation method and uses thereof. The X-ray diffraction pattern (CuK? radiation) of the crystal form of (R)-praziquantel at 25° C. shows the following diffraction peaks: 2-Theta=6.9±0.2°, 8.3±0.2°, 15.1±0.2°, 17.4±0.2°, 19.8±0.2°, 21.9±0.2°, 24.3±0.2° or d=12.74±0.20 ?, 10.61±0.20 ?, 5.87±0.20 ?, 5.09±0.20 ?, 4.48±0.20 ?, 4.06±0.20 ?, 3.66±0.20 ?. Compared to the existing crystal form of praziquantel, the crystal form of the present invention has better solubility, better drug efficacy and better pharmacokinetic characteristics. The preparation method of the present invention has the following advantages: good reproducibility, environmentally friendly, low cost, and able to operate at a normal pressure and temperature, and suitable for large-scale production.Type: ApplicationFiled: October 16, 2014Publication date: September 22, 2016Inventors: Mingxin Qian, Rodney JY Ho, Chunsheng Qiao, Junwei Shi
-
Publication number: 20160228579Abstract: The present invention relates to lipid-associated indocyanine green particles for enhanced functional high-resolution near-infrared fluorescence medical imaging of lymphatic vessels, lymph nodes, lymphatic abnormalities, tumors, and inflammation.Type: ApplicationFiled: May 29, 2015Publication date: August 11, 2016Inventors: Rodney J.Y. Ho, John C. Kraft, II, Mingxin Qian
-
Patent number: 9175321Abstract: Provided are R-praziquantel preparation methods, which utilize the characteristics of biological enzyme of strong stereoselectivity, site-selectivity, and regioselectivity, of high resolution efficiency, of mild reaction conditions, and of simple operations to catalyze the hydrolysis of a certain enantiomer in a chemically synthesized racemate or a derivative, thus acquiring a mixture of reacted and unreacted optical isomers. R-praziquantel prepared by the method can have a purity of 98% or more.Type: GrantFiled: October 26, 2012Date of Patent: November 3, 2015Assignee: SUZHOU TONGLI BIOMEDICAL CO., LTDInventor: Mingxin Qian
-
Patent number: 9139859Abstract: The invention relates to a new method for preparing (R)-praziquantel. In the invention, by taking advantage of the high stereo selectivity, site selectivity and region selectivity of an enzyme, an intermediate of a pure optical and chiral (R)-praziquantel are obtained by means of the dynamic kinetic resolution of an enantiomer from the synthesized racemate or derivatives thereof, and the (R)-praziquantel is obtained by using various conventional and mature organic chemical reactions with higher yield. The method of the invention has the potential advantages of easily available raw materials, low cost, environmentally safer process and convenience for large-scale production. Also, the purity of the end product can be more than 98%. By adopting the invention, the quality of the product is improved and a basis for developing high quality of active pharmaceutical ingredients and formulations is established, and thus the pending industrial problem of purifying praziquantel over 30 years becomes solvable.Type: GrantFiled: August 28, 2014Date of Patent: September 22, 2015Assignee: TONGLI BIOMEDICAL CO., LTDInventor: Mingxin Qian
-
Patent number: 9068214Abstract: The invention relates to a new method for preparing (R)-praziquantel. In the invention, by taking advantage of the high stereo selectivity, site selectivity and region selectivity of an enzyme, an intermediate of a pure optical and chiral (R)-praziquantel are obtained by means of the dynamic kinetic resolution of an enantiomer from the synthesized racemate or derivatives thereof, and the (R)-praziquantel is obtained by using various conventional and mature organic chemical reactions with higher yield. The method of the invention has the potential advantages of easily available raw materials, low cost, environmentally safer process and convenience for large-scale production. Also, the purity of the end product can be more than 98%. By adopting the invention, the quality of the product is improved and a basis for developing high quality of active pharmaceutical ingredients and formulations is established, and thus the pending industrial problem of purifying praziquantel over 30 years becomes solvable.Type: GrantFiled: August 28, 2014Date of Patent: June 30, 2015Assignee: Tongli Biomedical Co., LtdInventor: Mingxin Qian
-
Publication number: 20140370556Abstract: The invention relates to a new method for preparing (R)-praziquantel. In the invention, by taking advantage of the high stereo selectivity, site selectivity and region selectivity of an enzyme, an intermediate of a pure optical and chiral (R)-praziquantel are obtained by means of the dynamic kinetic resolution of an enantiomer from the synthesized racemate or derivatives thereof, and the (R)-praziquantel is obtained by using various conventional and mature organic chemical reactions with higher yield. The method of the invention has the potential advantages of easily available raw materials, low cost, environmentally safer process and convenience for large-scale production. Also, the purity of the end product can be more than 98%. By adopting the invention, the quality of the product is improved and a basis for developing high quality of active pharmaceutical ingredients and formulations is established, and thus the pending industrial problem of purifying praziquantel over 30 years becomes solvable.Type: ApplicationFiled: August 28, 2014Publication date: December 18, 2014Inventor: Mingxin Qian
-
Publication number: 20140370555Abstract: The invention relates to a new method for preparing (R)-praziquantel. In the invention, by taking advantage of the high stereo selectivity, site selectivity and region selectivity of an enzyme, an intermediate of a pure optical and chiral (R)-praziquantel are obtained by means of the dynamic kinetic resolution of an enantiomer from the synthesized racemate or derivatives thereof, and the (R)-praziquantel is obtained by using various conventional and mature organic chemical reactions with higher yield. The method of the invention has the potential advantages of easily available raw materials, low cost, environmentally safer process and convenience for large-scale production. Also, the purity of the end product can be more than 98%. By adopting the invention, the quality of the product is improved and a basis for developing high quality of active pharmaceutical ingredients and formulations is established, and thus the pending industrial problem of purifying praziquantel over 30 years becomes solvable.Type: ApplicationFiled: August 28, 2014Publication date: December 18, 2014Inventor: Mingxin Qian
-
Publication number: 20140256003Abstract: Provided are R-praziquantel preparation methods, which utilize the characteristics of biological enzyme of strong stereoselectivity, site-selectivity, and regioselectivity, of high resolution efficiency, of mild reaction conditions, and of simple operations to catalyze the hydrolysis of a certain enantiomer in a chemically synthesized racemate or a derivative, thus acquiring a mixture of reacted and unreacted optical isomers. R-praziquantel prepared by the method can have a purity of 98% or more.Type: ApplicationFiled: October 26, 2012Publication date: September 11, 2014Applicant: Suzhou Tongli Biomedical Co., Ltd.Inventor: Mingxin Qian